IHEM-CONICET, Av del libertador, 80, Mendoza, Argentina.
Facultad de Ciencias Médicas, Av del Libertador 80, Universidad Nacional de Cuyo, Mendoza, Argentina.
BMC Cancer. 2019 Apr 5;19(1):328. doi: 10.1186/s12885-019-5550-3.
Cancer cells evolve and constitute heterogeneous populations that fluctuate in space and time and are subjected to selection generating intratumor heterogeneity. This phenomenon is determined by the acquisition of genetic/epigenetic alterations and their selection over time which has clinical implications on drug resistance.
DNA extracted from different tumor cell populations (breast carcinomas, cancer cell lines and cellular clones) were analyzed by MS-MLPA. Methylation profiles were used to generate a heterogeneity index to quantify the magnitude of epigenetic heterogeneity in these populations. Cellular clones were obtained from single cells derived of MDA-MB 231 cancer cell lines applying serial limiting dilution method and morphology was analyzed by optical microscopy and flow cytometry. Clones characteristics were examined through cellular proliferation, migration capacity and apoptosis. Heterogeneity index was also calculated from beta values derived from methylation profiles of TCGA tumors.
The study of methylation profiles of 23 fresh breast carcinomas revealed heterogeneous allele populations in these tumor pieces. With the purpose to measure the magnitude of epigenetic heterogeneity, we developed an heterogeneity index based on methylation information and observed that all tumors present their own heterogeneity level. Applying the index calculation in pure cancer cell populations such as cancer cell lines (MDA-MB 231, MCF-7, T47D, HeLa and K-562), we also observed epigenetic heterogeneity. In addition, we detected that clones obtained from the MDA-MB 231 cancer cell line generated their own new heterogeneity over time. Using TCGA tumors, we determined that the heterogeneity index correlated with prognostic and predictive factors like tumor size (p = 0.0088), number of affected axillary nodes (p = 0.007), estrogen receptor expression (p < 0.0001) and HER2 positivity (p = 0.0007). When we analyzed molecular subtypes we found that they presented different heterogeneity levels. Interestingly, we also observed that all mentioned tumor cell populations shared a similar Heterogeneity index (HI) mean.
Our results show that each tumor presents a unique epigenetic heterogeneity level, which is associated with prognostic and predictive factors. We also observe that breast tumor subtypes differ in terms of epigenetic heterogeneity, which could serve as a new contribution to understand the different prognosis of these groups.
癌细胞在空间和时间上不断演变,构成异质群体,并受到选择的影响,从而产生肿瘤内异质性。这种现象是由遗传/表观遗传改变的获得及其随时间的选择决定的,这对药物耐药性具有临床意义。
从不同的肿瘤细胞群体(乳腺癌、癌细胞系和细胞克隆)中提取 DNA,通过 MS-MLPA 进行分析。使用甲基化谱生成异质指数,以量化这些群体中表观遗传异质性的程度。通过连续有限稀释法从 MDA-MB 231 癌细胞系中获得单细胞衍生的细胞克隆,并通过光学显微镜和流式细胞术分析形态。通过细胞增殖、迁移能力和凋亡检查克隆特征。还从 TCGA 肿瘤的β值衍生计算异质指数。
对 23 例新鲜乳腺癌的甲基化谱研究表明,这些肿瘤组织中存在异质等位基因群体。为了测量表观遗传异质性的程度,我们开发了一种基于甲基化信息的异质指数,并观察到所有肿瘤都具有自己的异质性水平。在 MDA-MB 231、MCF-7、T47D、HeLa 和 K-562 等纯癌细胞群体中应用指数计算,我们也观察到了表观遗传异质性。此外,我们发现从 MDA-MB 231 癌细胞系获得的克隆随着时间的推移会产生自己的新异质性。使用 TCGA 肿瘤,我们确定异质指数与肿瘤大小(p=0.0088)、受影响腋窝淋巴结数(p=0.007)、雌激素受体表达(p<0.0001)和 HER2 阳性(p=0.0007)等预后和预测因素相关。当我们分析分子亚型时,我们发现它们表现出不同的异质性水平。有趣的是,我们还观察到所有提到的肿瘤细胞群体都具有相似的异质指数(HI)均值。
我们的研究结果表明,每个肿瘤都具有独特的表观遗传异质性水平,与预后和预测因素相关。我们还观察到,乳腺癌亚型在表观遗传异质性方面存在差异,这可能有助于更好地理解这些群体的不同预后。